RNA Isoforms as Broad Targets for Cancer Immunotherapy

Area of Science:

• Oncology
• Immunology
• Bioinformatics

Background:

• Immunotherapy is often limited to cancers with high mutational burden.
• Post-transcriptional regulation generates neoantigens, a potential source for new cancer therapies.
• Alternative mRNA isoforms represent an untapped reservoir of immunogenic targets.

Purpose of the Study:

• To review emerging technologies for precision immune targeting of malignancies.
• To explore unconventional molecular targets, focusing on alternative mRNA isoforms.
• To discuss challenges and strategies for alternative isoform immune targeting.

Main Methods:

• Review of current literature on immunotherapy and neoantigen discovery.
• Focus on technologies for identifying and validating alternative mRNA isoforms.
• Discussion of in silico prioritization and high-throughput validation methods.

Main Results:

• Alternative mRNA isoforms can yield broadly presented neoantigens and cell surface proteins.
• New technologies enable the identification of these unconventional targets.
• In silico prioritization is crucial for validating alternative isoform targets.

Conclusions:

• Targeting alternative mRNA isoforms presents a promising avenue for developing novel cancer immunotherapies.
• This approach could expand treatment options beyond patients with high mutational burden.
• Overcoming challenges in validation and prioritization is key to clinical translation.